propargylamine

Known as: propinylamine 
 

Topic mentions per year

Topic mentions per year

1974-2017
0102019742017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
HIGHLIGHTS ASS2324 is a hybrid compound resulting from the juxtaposition of donepezil and the propargylamine PF9601N ASS2324 is a… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
We recently reported that propargylamine derivatives such as rasagiline (Azilect) and its S-isomer TVP1022 are neuroprotective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
The anti-Parkinson drug, rasagiline (N-propargyl-(1R)-aminoindan) promotes neuronal survival, via neuroprotective activity… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
In Parkinson's disease and other neurodegenerative diseases, (- )deprenyl, an inhibitor of type B monoamine oxidase (MAO-B), has… (More)
  • table 1
Is this relevant?
2003
2003
Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
(-)-Deprenyl and structurally related propargylamines increase neuronal survival independently of monoamine oxidase B (MAO-B… (More)
Is this relevant?
2000
2000
A potent inhibitor of type B monoamine oxidase, (-)deprenyl, is known to protect or rescue dying neurons, independent of… (More)
Is this relevant?
2000
2000
The ability of CGP 3466B to attenuate the behavioural and morphological consequences of experimentally induced cell death was… (More)
Is this relevant?
1994
1994
Aliphatic N-propargylamines have recently been discovered to be highly potent, selective, and irreversible monoamine oxidase B… (More)
Is this relevant?
1992
1992
A series of aliphatic propargylamine derivatives has been synthesized. Some of them possess highly potent, irreversible… (More)
Is this relevant?